Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02298387

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Advanced Solid Tumor Malignancies Clinical Trial

Official title:
A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors

Clinical Trial Summary

This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.

Clinical Trial Description

This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy. ;

Study Design

Related Conditions & MeSH terms

  • Advanced Solid Tumor Malignancies
  • Neoplasms
Clinical Trial Details
NCT number NCT02298387
Study type Interventional
Source Mereo BioPharma
Contact
Status Completed
Phase Phase 1
Start date December 22, 2014
Completion date September 8, 2017
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT05791474 - ATI-2231 in Advanced Solid Tumor Malignancies Phase 1
Completed NCT00996515 - A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies Phase 1
Active, not recruiting NCT01522989 - PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies Phase 1